Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD40.RBDv Vaccine Booster in Healthy Volunteers
NCT06255626Phase 2Recruiting
- Sponsor
- ANRS
- Start
- May 2024
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CD40.RBDv in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by ANRS. Primary endpoints: Proportion of participants without any grade 3 or 4 biological or clinical solicited local/systemic or unsolicited AEs at Month 3 and Neutralization antibodies titers (anti-RBD) at Month 1. Started May 2024; status: recruiting.
02
Drugs
CD40.RBDv
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06255626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255626.